Sorafenib is an orally administered multitarget tyrosine kinase inhibitor that exerts antitumor effects by inhibiting angiogenesis and tumor cell proliferation through targeting the vascular endothelial growth factor receptor (VEGFR) family. The gene discussed is KDR; the disease is neoplasm.